IsoRay (ISR) Builds on Conference Momentum

NEW YORK (TheStreet) -- IsoRay (ISR) is rallying for its third consecutive day as positive sentiment surrounding the company's participation in a major medical conference gains momentum.

By midafternoon, shares had added 5.1% to $3.28. Since the beginning of the year, the stock has exploded 558%.

Trading volume of 19.6 million shares had exceeded its three-month daily average of 13.2 million.

From Thursday to Saturday, the radioisotope specialist will host a booth at the Annual Meeting of the American Brachytherapy Society (ABS) in San Diego.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

In addition, IsoRay's Cesium-131 will feature in five separate panels where prominent specialists will discuss their experiences. Cesium-131 is a method of concentrating radiation in cancer treatment.

"Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used," said CEO Dwight Babcock in a statement.

"With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients," he continued.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Insider Trading Alert - STRP, ISR And TCRD Traded By Insiders

Insider Trading Alert - ISR, AAT And FB Traded By Insiders

Insider Trading Alert - ISR, SIX And SUMR Traded By Insiders

Strong On High Volume: IsoRay (ISR)

Trade-Ideas: IsoRay (ISR) Is Today's "Dead Cat Bounce" Stock